… and mortality of severe COVID-19, the role of anticoagulation … heparin (LMWH) or subcutaneous
unfractionated heparin (UFH) … ) or direct oral anticoagulants (DOACs) (apixaban, one …

… or therapeutic anticoagulants in reducing mortality and … with fulldose heparin-based
anticoagulation than in those … , or therapeutic-dose apixaban. After 30 days, there was no …

… Danish national guidelines recommended dosages: apixaban and dabigatranetexilat – two
tablets a … the possible benefit of other anticoagulants such as heparins in COVID-19 patients. …

… The efficacy of low-molecular-weight heparin (LMWH) doses … risk of mortality in patients
with the severe form of COVID-19 [… and Apixaban) in four out of five hospitalized COVID-19 …

… (eg, renal function, history of heparin-induced thrombocytopenia, concerns … impact. As of
28 October 2020, over 44 million cases and 1.1 million deaths had been attributed to COVID-19…

… heparin (enoxaparin) versus standard of care (no enoxaparin) … patients with COVID-19 treated
with aspirin or apixaban versus … that anticoagulation was associated with lower mortality in …

… cases and over 2,500,000 deaths.Recent observations … Enoxaparin was the first low
molecular weight heparin to be … findings of anticoagulation dosing regimens in COVID-19 but …

… dose of Enoxaparin (40 mg SubQ daily) or Heparin (5000-unit … lowest mortality rates for
COVID-19. Low molecular weight … oral therapeutic anticoagulation like Apixaban or Rivaroxaban …

… covid-19 found no conclusive benefits of high dose low-molecular-weight heparin or
unfractionated heparin … treatment, or mortality among patients with covid-19 admitted to the …

… COVID-19, contributing to significant morbidity and mortality [… anticoagulation, mainly
heparin, in hospitalized COVID-19 … dose aspirin, 2.5 mg apixaban, 5 mg apixaban, and placebo. …